206 related articles for article (PubMed ID: 15150125)
1. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor.
Demidenko ZN; Blagosklonny MV
Cancer Res; 2004 May; 64(10):3653-60. PubMed ID: 15150125
[TBL] [Abstract][Full Text] [Related]
2. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
[TBL] [Abstract][Full Text] [Related]
3. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
4. Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
Li Y; Raffo AJ; Drew L; Mao Y; Tran A; Petrylak DP; Fine RL
Cancer Res; 2003 Apr; 63(7):1527-33. PubMed ID: 12670900
[TBL] [Abstract][Full Text] [Related]
5. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.
Rosato RR; Almenara JA; Cartee L; Betts V; Chellappan SP; Grant S
Mol Cancer Ther; 2002 Feb; 1(4):253-66. PubMed ID: 12467221
[TBL] [Abstract][Full Text] [Related]
6. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
[TBL] [Abstract][Full Text] [Related]
8. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.
Rosato RR; Almenara JA; Yu C; Grant S
Mol Pharmacol; 2004 Mar; 65(3):571-81. PubMed ID: 14978235
[TBL] [Abstract][Full Text] [Related]
9. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
10. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells.
Hastak K; Gupta S; Ahmad N; Agarwal MK; Agarwal ML; Mukhtar H
Oncogene; 2003 Jul; 22(31):4851-9. PubMed ID: 12894226
[TBL] [Abstract][Full Text] [Related]
11. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Almenara J; Rosato R; Grant S
Leukemia; 2002 Jul; 16(7):1331-43. PubMed ID: 12094258
[TBL] [Abstract][Full Text] [Related]
12. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway.
Alonso M; Tamasdan C; Miller DC; Newcomb EW
Mol Cancer Ther; 2003 Feb; 2(2):139-50. PubMed ID: 12589031
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel.
Blagosklonny MV; Darzynkiewicz Z; Figg WD
Cancer Biol Ther; 2002; 1(4):420-5. PubMed ID: 12432259
[TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways.
Cartee L; Smith R; Dai Y; Rahmani M; Rosato R; Almenara J; Dent P; Grant S
Mol Pharmacol; 2002 Jun; 61(6):1313-21. PubMed ID: 12021392
[TBL] [Abstract][Full Text] [Related]
16. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.
Shapiro GI; Koestner DA; Matranga CB; Rollins BJ
Clin Cancer Res; 1999 Oct; 5(10):2925-38. PubMed ID: 10537362
[TBL] [Abstract][Full Text] [Related]
17. Diversity of the apoptotic response to chemotherapy in childhood leukemia.
Liu T; Raetz E; Moos PJ; Perkins SL; Bruggers CS; Smith F; Carroll WL
Leukemia; 2002 Feb; 16(2):223-32. PubMed ID: 11840289
[TBL] [Abstract][Full Text] [Related]
18. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
Li W; Fan J; Bertino JR
Cancer Res; 2001 Mar; 61(6):2579-82. PubMed ID: 11289134
[TBL] [Abstract][Full Text] [Related]
19. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.
Wittmann S; Bali P; Donapaty S; Nimmanapalli R; Guo F; Yamaguchi H; Huang M; Jove R; Wang HG; Bhalla K
Cancer Res; 2003 Jan; 63(1):93-9. PubMed ID: 12517783
[TBL] [Abstract][Full Text] [Related]
20. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
Ambrosini G; Seelman SL; Qin LX; Schwartz GK
Cancer Res; 2008 Apr; 68(7):2312-20. PubMed ID: 18381438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
